FDA Clearance Tracker · K212779
Coag-Sense Prothrombin (PT) / INR Monitoring System for Patient Self-Testing
Last checked: Nov 19, 2026Latest source record: Oct 5, 2022 (this decision)Source: openFDAMethods & limitations
Decided
Oct 5, 2022
Substantially Equivalent
Time to decision
399 days
Received Sep 1, 2021. Calendar days, including time FDA spent waiting on the applicant.
Pathway
510(k)
Special
Device class
Class II
The decision
- FDA number
- K212779
- Device name
- Coag-Sense Prothrombin (PT) / INR Monitoring System for Patient Self-Testing
- Applicant
- Coagusense, Inc.
- Applicant location
- Fremont, CA
- Received
- Sep 1, 2021
- Decided
- Oct 5, 2022
- Decision
- Substantially Equivalent
- Submission type
- Special
Device type
- Device type
- Test, Time, Prothrombin (GJS)
- Device class
- Class II
- Regulation
- 21 CFR 864.7750
- Specialty
- Laboratory Medicine & Pathology
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code GJS. The earliest in FDA's data is K780203, decided Mar 27, 1978.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
- FDA database record for K212779
- 510(k) summary (PDF) · FDA posts these some weeks after the decision, so a recent one may not open yet.
The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.
Other decisions for Coagusense, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K183255 · Decided Feb 21, 2019 · 92 days after receipt
Device type: Test, Time, Prothrombin (GJS) · Laboratory Medicine & Pathology
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.